Odonate Therapeutics, Inc.
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Odonate Therapeutics, Inc. ("Odonate") on behalf of stockholders. A class action complaint has been filed against Odonate, which alleges that defendants made materially false and misleading statements regarding Odonate's business, operational, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) tesetaxel was not as safe or well-tolerated as Odonate had led investors to believe; (ii) thus, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) accordingly, Odonate's public statements were materially false and misleading at all relevant times.